Oct, 2017

Sep, 2017

Global
News / General News
Pfizer Contacts: For MediaSally Beatty(212) 733-6566sally.beatty@pfizer.com  For InvestorsChuck Triano(212) 733-3901 charles.e.triano@pfizer.com  Astellas Contact: For MediaTyler Marciniak (847) 736-7145tyler.marciniak@astellas.com For InvestorsSo Sekine (847) 224-9557sou.sekine@astellas.com  Pfizer and Astellas Announce Positive Top-Line Results from Phase 3 PROSPER Trial of XTANDI (e...
Read More
Global
News / General News
If approved, the combination therapy could potentially offer a new treatment option for patients whose overactive bladder symptoms are not adequately controlled on monotherapy Tokyo, Sept. 12, 2017 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Ap...
Read More
Global
News / General News
  Tokyo, September 11, 2017  - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that it has submitted a supplemental new drug application for marketing approval of the guanylate cyclase-C receptor agonist “linaclotide (generic name) (brand name: Linzess® Tablets 0.25 mg)” for the additional indication of chronic constipation (other than constipa...
Read More
Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.

Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.

Nothing Found

Unfortunately, we weren't able to find a match for your search query. Please try again.